897-B A DNAJB1-PRKACA fusion peptide vaccine combined with ipilimumab and nivolumab elicits polyclonal fusion-specific T cell responses in fibrolamellar carcinoma

• Mark Yarchoan,
• Paul G Thomas,
• Allison M Kirk,
• Jeremy C Crawford,
• Zeal Kamdar,
• Marina Baretti

Affiliations

Mark Yarchoan

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Paul G Thomas

1 Department of Immunology, St Jude Children`s Research Hospital, Memphis, Tennessee, USA

Allison M Kirk

1St. Jude Children’s Research Hospital, Memphis, TN, USA

Jeremy C Crawford

1St. Jude Children’s Research Hospital, Memphis, TN, USA

Zeal Kamdar

2Johns Hopkins University School of Medicine, Baltimore, MD, USA

Marina Baretti

2Johns Hopkins University School of Medicine, Baltimore, MD, USA